人肝肿瘤细胞系生物人工肝治疗重型肝炎的临床初步研究

目的观察人肝肿瘤细胞系生物人工肝治疗重型肝炎病人的临床疗效和安全性。方法对5例重型肝炎病人先行持续的血浆透析滤过和血浆置换,次日进行持续72h的人肝肿瘤细胞系生物人工肝支持治疗,观察患者转归。结果治疗后患者总胆红素由212.0±74.8μmol/L降至145.3±88.7μmol/L(P0.05),8周后降至23.4±6.0μmol/L(P0.01);血清AFP从158.4±99.7ng/ml升高至903.7±66.3ng/m(lP0.05),但在8周后明显下降到95.1±58ng/ml;凝血酶原活动度在治疗中一度下降,但治疗2周后明显恢复。最终3例病人临床痊愈出院,1例好转,1例死亡。结论人肝肿瘤细胞系生物人工肝支持系统可用于重型肝炎患者的治疗,并无严重的副反应发生。

Preliminary clinical observation of liver assist device with human hepatoma cell line on patients with severe hepatitis

Objective To investigate the therapeutic effects and safety of liver assist device with human hepatoma cell line on patients with severe hepatitis.Method Five patients with liver failure were treated with continuous hematoplasma dialysis filtration and were supported by liver assist device with C3A cell line for 72 hours.Result Three patients recovered from the liver failure,1 improved and 1 died;After treatment,level of AFP were significant increased （P0.05）,while the TBIL decreased in the patients （P0.05）,But the level of ammonia and albumin had no significant change.During the treatment,there was no severe complication such as hemorrhage and allergic reaction.Conclusions Liver assist device with human hepatoma cell line may be an alternative method to treat patients with liver failure.